GlobeNewswire: Cybin Inc. Contains the last 10 of 13 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T20:16:33ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2022/03/07/2397973/0/en/Cybin-Inc-NEO-CYBN-NYSE-American-CYBN-Leads-Out-in-Psychedelic-Based-Therapeutics-Space.html?f=22&fvtc=4&fvtv=61497Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Leads Out in Psychedelic-Based Therapeutics Space 2022-03-07T13:30:00Z<![CDATA[NEW YORK, March 07, 2022 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) announces the availability of a broadcast titled, “Psychedelic Therapies Offer Hope for Mental Health.”]]>https://www.globenewswire.com/news-release/2022/03/03/2396324/0/en/Cybin-Inc-NEO-CYBN-NYSE-American-CYBN-Unleashing-Power-of-Psychedelics.html?f=22&fvtc=4&fvtv=61497Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Unleashing Power of Psychedelics2022-03-03T13:30:00Z<![CDATA[NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) -- via InvestorWire — Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trusted brands within the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities.]]>https://www.globenewswire.com/news-release/2021/03/26/2200061/0/en/Cybin-Inc-NEO-CYBN-at-Forefront-of-Psychedelic-Revolution.html?f=22&fvtc=4&fvtv=61497Cybin Inc. (NEO: CYBN) at Forefront of Psychedelic Revolution2021-03-26T12:30:00Z<![CDATA[NEW YORK, March 26, 2021 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Cybin Inc. (NEO: CYBN) announces the availability of a broadcast titled, “Science Drives Surging Interest in Psychedelic Therapeutics.”]]>https://www.globenewswire.com/news-release/2021/03/25/2199300/0/en/Cybin-Inc-NEO-CYBN-in-Prime-Position-as-Interest-in-Psychedelic-Medicine-Surges.html?f=22&fvtc=4&fvtv=61497Cybin Inc. (NEO: CYBN) in Prime Position as Interest in Psychedelic Medicine Surges2021-03-25T12:30:00Z<![CDATA[NEW YORK, March 25, 2021 (GLOBE NEWSWIRE) -- via InvestorWire — Cybin Inc. (NEO: CYBN) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trusted brands within the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities.]]>https://www.globenewswire.com/news-release/2020/12/18/2147827/0/en/Cybin-Inc-NEO-CYBN-Looking-to-Solve-Long-Standing-Problem-with-MDD-Treatment.html?f=22&fvtc=4&fvtv=61497Cybin Inc. (NEO: CYBN) Looking to Solve Long-Standing Problem with MDD Treatment2020-12-18T13:30:00Z<![CDATA[NEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Cybin Inc. (NEO: CYBN) announces the availability of a broadcast titled, “Hope on the Horizon: Psychedelics Offer Potential for Transforming Mental Health Treatments.”]]>https://www.globenewswire.com/news-release/2020/12/17/2146975/0/en/Cybin-Inc-NEO-CYBN-Acquisition-Three-Pillar-Approach-Reason-for-Optimistic-MDD-Outlook.html?f=22&fvtc=4&fvtv=61497Cybin Inc. (NEO: CYBN) Acquisition, Three-Pillar Approach Reason for Optimistic MDD Outlook 2020-12-17T13:30:00Z<![CDATA[NEW YORK, Dec. 17, 2020 (GLOBE NEWSWIRE) -- via InvestorWire — Cybin Inc. (NEO: CYBN) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trusted brands within the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities.]]>https://www.globenewswire.com/news-release/2020/12/14/2144546/0/en/CYBIN-Closes-Acquisition-of-Adelia-Therapeutics-Bolsters-Scientific-Team-and-Grows-IP-Portfolio-to-7-Patent-Filings.html?f=22&fvtc=4&fvtv=61497CYBIN Closes Acquisition of Adelia Therapeutics; Bolsters Scientific Team and Grows IP Portfolio to 7 Patent Filings2020-12-14T13:51:58Z<![CDATA[--Newly acquired novel psychedelic molecules diversify Cybin’s development portfolio, providing access to multiple future indications----Adelia brings a range of technologies related to novel therapeutics, delivery methods, and therapeutic regimens, along with six patent applications--]]>https://www.globenewswire.com/news-release/2020/12/14/2144494/0/en/CYBIN-Closes-Acquisition-of-Adelia-Therapeutics-Bolsters-Scientific-Team-and-Grows-IP-Portfolio-to-7-Patent-Filings.html?f=22&fvtc=4&fvtv=61497CYBIN Closes Acquisition of Adelia Therapeutics; Bolsters Scientific Team and Grows IP Portfolio to 7 Patent Filings2020-12-14T13:07:03Z<![CDATA[--Newly acquired novel psychedelic molecules diversify Cybin’s development portfolio, providing access to multiple future indications----Adelia brings a range of technologies related to novel therapeutics, delivery methods, and therapeutic regimens, along with six patent applications--]]>https://www.globenewswire.com/news-release/2020/11/13/2126505/0/en/New-Study-Finds-Psychedelic-Treatments-More-Effective-than-Typical-Antidepressant-Medications.html?f=22&fvtc=4&fvtv=61497New Study Finds Psychedelic Treatments More Effective than Typical Antidepressant Medications 2020-11-13T13:30:00Z<![CDATA[NEW YORK, Nov. 13, 2020 (GLOBE NEWSWIRE) -- via NetworkNewsAudio – Cybin Inc. (NEO: CYBN) announces the availability of a broadcast titled, “On the Trail of Better Therapeutics for Depression.”]]>https://www.globenewswire.com/news-release/2020/11/11/2124745/0/en/New-Therapeutic-Protocols-Targeting-Debilitating-Disorders-on-the-Horizon.html?f=22&fvtc=4&fvtv=61497New Therapeutic Protocols Targeting Debilitating Disorders on the Horizon2020-11-11T13:30:00Z<![CDATA[NEW YORK, Nov. 11, 2020 (GLOBE NEWSWIRE) -- via InvestorWire — Cybin Inc. (NEO: CYBN) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trusted brands within the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities.]]>